Moderna dépose une demande d'homologation pour le vaccin Covid mis à jour
Published: Thursday, Jul 13th 2023, 15:00
Mise à jour le : Vendredi, 13 octobre 2023, 14:12
Retour au fil d'actualité
Moderna, a biotechnology company based in the US, has submitted an application for approval of its updated Covid-vaccine in Switzerland. The XBB.1.5-vaccine is said to trigger an immune response against the XBB-lineage of Coronaviruses. Preliminary clinical tests have shown that the vaccine is effective against the XBB-variants of Covid-19 currently circulating in Switzerland. The World Health Organisation (WHO) has stated that the original strain and related variants of the Coronavirus are no longer circulating in humans. Global regulatory and health authorities have recommended updating Covid-vaccines to XBB.1.5-variants for a robust immune response against currently circulating variants. Moderna has presented a pre-clinical trial and preliminary clinical studies to Swissmedic, the Swiss regulatory authority, showing the vaccine to be effective against XBB-sub-lines.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic